戻る Agenda
Session 1a Focus on New Product Registration
Session Chair(s)
Thean Soo Lo
Regulatory Affairs Management Consultant
TS Consulting, Singapore
Helene Sou, MSC, RAC
Global Regulatory Policy and Innovation
Takeda Pharmaceutical Company Limited., Singapore
Speaker(s)
Hybrid ACCESS/ORBIS Type C Pathway: 1st Industry Experience, Process, Benefits and Considerations
Mi-Young Park
Takeda, Singapore
Senior Regulatory Affairs Director, Growth and Emerging Markets
Edana Loke
AbbVie Pte Ltd, Singapore, Singapore
Director, JAPAC Regulatory Policy and Intelligence
Perspectives on Regulatory Reliance and the TGA Experience
Paul Huleatt, PHD
Therapeutic Goods Administration (TGA), Singapore
Indo-Pacific Regulatory Strengthening Program Intl Regulatory Branch
Accelerating and Streamlining Regulatory Processes
Yuriko Takemura
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Coordinator, Division of Asia II, Office of International Programs
Yee Hoo Looi, PHD
Therapeutic Products Branch, HSA, Singapore
Deputy Director